Banca de QUALIFICAÇÃO: RAYSSA DIAS FALEIRO

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
DISCENTE : RAYSSA DIAS FALEIRO
DATA : 30/10/2018
HORA: 17:27
LOCAL: PPGMV/IV/UFRRJ
TÍTULO:

Study of the heart rate variability associated with the use of cholinergic antagonist (1% atropine) in dogs (Canis familiaris, LINNAEUS, 1758) with ulcerative keratitis.

PALAVRAS-CHAVES:

Corneal ulcer, mydriatic, cycloplegic.

PÁGINAS: 26
GRANDE ÁREA: Ciências Agrárias
ÁREA: Medicina Veterinária
SUBÁREA: Clínica e Cirurgia Animal
ESPECIALIDADE: Clínica Veterinária
RESUMO:

The cornea is the outermost portion of the ocular bulb and, due to its anatomical location, is often subject to harmful processes. Ulcerative keratitis is one of the most common causes of eye disease and can lead to vision loss if you do not receive the correct treatment. Atropine is the eye drops used to induce mydriasis and cycloplegia, avoiding the formation of synechiae. After instillation, it is absorbed into the systemic circulation and can promote important systemic side effects. Continuous electrocardiography allows the evaluation of heart rate variability, indicating the autonomic modulation of the heart. The objective of the present study is to evaluate the influence of treatment with atropine 1% eye drops on the heart rate variability of dogs with ulcerative keratitis. However, it is expected that dogs with ulcerated keratitis treated with 1% atropine present an increase in heart rate, with consequent decrease in their variability, due to parasympathetic blockade. Therefore, the study of the heart rate variability before and after treatment with a cholinergic antagonist may bring us the knowledge of the sympathetic stimulation and its clinical consequences, and the possibility of improving the autonomic balancing after termination of the treatment, increasing the quality and life expectancy of these patients patients. For the study, 30 healthy dogs diagnosed with ulcerative keratitis will be included. Will be evaluated the heart rate variability before instillation of atropine 1% eye drops (T0), with five days of treatment (T1) and fifteen days after treatment (T2).

MEMBROS DA BANCA:
Interno - 2318733 - DANIEL DE ALMEIDA BALTHAZAR
Interno - 4563410 - JULIO ISRAEL FERNANDES
Externo ao Programa - 386860 - JOAO TELHADO PEREIRA